An Evidence Atlas of Diagnostic Tests for Genitourinary Tuberculosis: A Laboratory-Centered Framework Authors: Hailing Zeng, Qiongfang Zhang Published: 2026 ABSTRACT AbstractBackgroundGenitourinary tuberculosis (GUTB) remains difficult to diagnose because of nonspecific clinical manifestations, low bacterial burden, and variability in diagnostic performance across laboratory methods and specimen types. However, the current evidence landscape of laboratory diagnostic tests for GUTB remains fragmented.MethodsA systematic literature review was conducted using PubMed, Embase, and Web of Science. Studies reporting laboratory diagnostic methods and diagnostic performance for GUTB were included. Core data regarding diagnostic methods, specimen types, diagnostic sensitivity, and turnaround time were extracted and integrated into an evidence atlas using evidence matrices, bubble plots, and Sankey diagrams.ResultsA total of 21 studies were included in the evidence atlas. Urine-related specimens were reported in 19 of 21 studies (90.5%), while first-morning urine specimens were used in 9 studies (42.9%). Molecular diagnostic methods, particularly Xpert MTB/RIF, polymerase chain reaction/nucleic acid amplification tests (PCR/NAAT), and simultaneous amplification testing for tuberculosis (SAT-TB), represented the most frequently investigated diagnostic approaches in urine-based specimens. PCR/NAAT-based methods showed reported diagnostic sensitivity ranging from 42.9% to 94.3%, whereas Xpert MTB/RIF demonstrated reported sensitivity ranging from 39.0% to 89.0% across included studies. Evidence matrix and Sankey diagram analyses showed that urine and first-morning urine combined with molecular diagnostic methods represented the most evidence-rich diagnostic pathway in the current literature. In contrast, evidence related to special specimen types, histological examinations, and emerging molecular diagnostic technologies remained limited.ConclusionThis evidence atlas provides a structured overview of the current evidence landscape of laboratory diagnostic tests for genitourinary tuberculosis. Urine-based specimens combined with molecular diagnostic methods currently represent the most extensively studied diagnostic pathway. Further studies involving special specimen types, emerging molecular diagnostic technologies, and high-risk populations are needed to strengthen the evidence base for laboratory diagnosis of genitourinary tuberculosis.Keywords: evidence atlas, genitourinary tuberculosis, laboratory diagnosis, molecular diagnostic methods Introduction Background and Rationale Tuberculosis (TB) remains a major global public health challenge. According to the World Health Organization (WHO) Global Tuberculosis Report 2025, an estimated 10.8 million people developed tuberculosis worldwide in 2023.1 Although pulmonary tuberculosis accounts for most reported cases, extrapulmonary tuberculosis remains an important clinical form of the disease. Genitourinary tuberculosis (GUTB) is an important manifestation of extrapulmonary tuberculosis and has been reported to account for approximately 15–20% of extrapulmonary tuberculosis cases in some series.2 GUTB is characterized by nonspecific clinical manifestations and low bacillary burden, which frequently contribute to delayed diagnosis and disease progression. Previous studies, including the work by Kamra et al, have highlighted that the varied clinical presentations of GUTB and the low positivity of conventional smear- and culture-based methods in paucibacillary specimens may create substantial diagnostic dilemmas in clinical practice.3 In clinical practice, GUTB may mimic urinary tract stones, cystitis, pyelonephritis, or malignancies, thereby increasing the risks of misdiagnosis and missed diagnosis. Delayed recognition of the disease may ultimately result in severe complications, including renal dysfunction, ureteral stricture, and fistula formation.3–6 Laboratory diagnosis of GUTB remains challenging because conventional diagnostic approaches, including acid-fast bacilli smear microscopy and mycobacterial culture, often demonstrate limited sensitivity in paucibacillary specimens. Although mycobacterial culture remains the microbiological reference standard, prolonged turnaround time may delay clinical decision-making. In recent years, molecular diagnostic technologies such as Xpert MTB/RIF, polymerase chain reaction/nucleic acid amplification tests (PCR/NAAT), and simultaneous amplification testing for tuberculosis (SAT-TB) have been increasingly applied for rapid detection of Mycobacterium tuberculosis in urine and other genitourinary specimens. Xpert MTB/RIF is a cartridge-based nucleic acid amplification test (CBNAAT) recommended by the World Health Organization for rapid detection of Mycobacterium tuberculosis and rifampicin resistance through identification of mutations in the rpoB gene (Rv0667). Previous studies have suggested that SAT-TB may provide relatively rapid detection with acceptable diagnostic performance in low-bacterial-load specimens, although evidence remains limited.2 Nevertheless, the diagnostic performance of different laboratory methods may vary substantially according to specimen type, bacterial load, and testing platform, and evidence regarding their comparative diagnostic value remains fragmented across studies. Although numerous studies have evaluated individual diagnostic methods for GUTB, the current evidence landscape remains fragmented, particularly with respect to relationships among specimen types, laboratory testing methods, diagnostic sensitivity, and turnaround time. To date, a comprehensive evidence atlas integrating these multidimensional diagnostic characteristics has not been systematically established. Mapping the distribution and characteristics of existing evidence may help identify evidence-rich areas, clarify current research gaps, and support optimization of laboratory diagnostic pathways for GUTB. Compared with several other forms of extrapulmonary tuberculosis, GUTB presents distinctive diagnostic challenges because of its nonspecific manifestations, low bacillary burden, and heavy reliance on urine-based laboratory testing, making it particularly suitable for evidence mapping of diagnostic pathways. Objectives and Structure of the Study Based on the above considerations, this study aimed to systematically map and evaluate the evidence landscape of laboratory diagnostic tests for genitourinary tuberculosis through a comprehensive literature review and construction of an evidence atlas. By integrating evidence related to diagnostic methods, specimen types, diagnostic sensitivity, and turnaround time, we sought to characterize current evidence distribution patterns and identify potential gaps requiring further investigation. Methods Design Framework of the Evidence Atlas This study adopted a laboratory-centered approach to construct an evidence atlas of diagnostic tests for genitourinary tuberculosis. The overall methodological framework consisted of several key steps: systematic identification and selection of high-quality literature, stratified extraction of core data related to laboratory diagnostics, standardized classification and appraisal of evidence for different diagnostic technologies, and multidimensional visualization to intuitively present evidence distribution and research hotspots. The design of the evidence atlas emphasized a structured synthesis of information on diagnostic methods, specimen types, sensitivity, and specificity, with the objective of elucidating the evidence structure and developmental trends of laboratory-based diagnostics in the field of genitourinary tuberculosis. Literature Search Strategy and Eligibility Criteria To comprehensively identify evidence related to laboratory diagnostic testing for genitourinary tuberculosis, a systematic literature search was conducted in PubMed, Embase, and Web of Science. No restrictions on publication date or language were applied in order to maximize coverage of potentially relevant studies. The search strategy was developed using combinations of subject headings and free-text terms related to “genitourinary tuberculosis”, “diagnostic tests”, “laboratory diagnostics”, and “urine specimens”. Detailed search strategies for each database are provided in Supplementary Table 1. The inclusion criteria were as follows: (1) studies involving patients with genitourinary tuberculosis; (2) studies reporting laboratory diagnostic methods and diagnostic performance indicators; (3) studies using urine or genitourinary system–related specimens; and (4) original studies, systematic reviews, or authoritative guidelines. The exclusion criteria included studies not related to genitourinary tuberculosis, studies lacking laboratory diagnostic data, and case reports or other publications without original data. Literature screening and study selection were independently performed by two reviewers, with discrepancies resolved through group discussion. Data Extraction and Management Following standard procedures for systematic reviews, two reviewers independently extracted key information from each included study. Extracted data included first author, year of publication, country, study design, total sample size, number of genitourinary tuberculosis cases, diagnostic methods, specimen types, specimen processing procedures, diagnostic categories, diagnostic sensitivity, and quality assessment or evidence level. All extracted data were compiled into structured tables to facilitate subsequent evidence stratification and visualization within the evidence atlas. Any disagreements during the data extraction process were resolved through discussion among all investigators to ensure data accuracy and reliability. Evidence Grading and Quality Assessment Evidence grading and quality assessment were conducted according to study type using appropriate methodological tools. Diagnostic accuracy studies were assessed for risk of bias and applicability using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. Other types of evidence were evaluated according to the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) levels of evidence. All assessments were independently performed by two reviewers, and disagreements were resolved through consensus among all investigators. Visualization Methods and Tools for Evidence Mapping After consolidation into structured tables, core data from all included studies were imported into R software for data processing and construction of the evidence atlas. The visualization outputs included evidence distribution maps, research hotspot maps, and association diagrams of key variables, enabling multidimensional and intuitive presentation of evidence distribution, diagnostic pathways, and research trends related to diagnostic tests. Zotero reference management software was used for literature retrieval, record management, and duplicate removal to ensure standardized and efficient study selection and data management. Results Study Selection A total of 3170 records were identified through systematic searches of PubMed, Embase, and Web of Science. After removal of duplicate records using reference management software, 2592 unique records remained. Following initial screening of titles and abstracts, 131 articles were assessed for full-text eligibility. Ultimately, 21 primary studies met the predefined inclusion and exclusion criteria and were included in the evidence atlas analysis. The detailed study selection process is presented in Figure 1 (PRISMA flow diagram). PRISMA flow diagram of study selection. Characteristics of Included Studies A total of 21 primary studies were ultimately included in this analysis, encompassing research conducted in multiple countries and regions, including China, India, the United States, and Ethiopia. The included studies were published between 1976 and 2025 and comprised various study designs, such as cross-sectional diagnostic studies and cohort studies. Sample sizes ranged from 44 to 302 participants, while the number of genitourinary tuberculosis cases varied from 11 to 186 across studies. A wide range of laboratory diagnostic methods was reported, including conventional bacteriological techniques (such as Löwenstein–Jensen culture, Mycobacteria Growth Indicator Tube culture, and acid-fast staining), molecular diagnostic methods (including polymerase chain reaction, simultaneous amplification testing for tuberculosis, and Xpert MTB/RIF), as well as histopathological examinations. Urine-related specimens were reported in 19 of 21 studies (90.5%). First-morning urine was used in 9 studies (42.9%), bladder tissue in 3 studies (14.3%), and 24-hour urine in 1 study (4.8%). Some studies also included tissue biopsies and other body fluid samples. Specimen processing procedures varied and included centrifugation, digestion, lysis buffer treatment, and resuspension in phosphate-buffered saline. Diagnostic categories covered molecular testing, culture, microscopy, histopathology, and imaging examinations. All included studies reported diagnostic sensitivity for at least one primary testing method, and several studies provided comparative evaluations of multiple diagnostic approaches. Detailed characteristics of the included studies are summarized in Table 1 and Supplementary Table 2. Table 1Characteristics of Included Studies on Laboratory Diagnostic Tests for Genitourinary TuberculosisAuthorCountryStudy DesignSample sizeDiagnostic MethodsSpecimen TypeSpecimen Processing MethodExamination CategorySensitivityYu Chen7 2019ChinaCross-sectional diagnostic study302Xpert MTB/RIF, MGIT 960 culture, fluorescent acid-fast stainingFirst-morning urineDirect lysis buffer addition, centrifugation, sediment collectionMolecular testing, culture, microscopyXpert MTB/RIF 41.30%Mallya A8 2019IndiaCohort study76Acid-fast staining, PCR, histopathology, IVU/CTU, erythrocyte sedimentation rate, chest X-rayUrine, tissue, IVU, CTU, ESR, chest X-rayNAMicroscopy, molecular testing, histopathology, imaging examinations, laboratory testsComposite Reference Standard (CRS) 34.20%, Xpert MTB/RIF 89.00%Zhao Wei2 2025ChinaCohort study69SAT-TB, Xpert MTB/RIF, MGIT 960 cultureFirst-morning urineCentrifugation, NALC–NaOH digestion, sediment collection, resuspension in PBSMolecular testing, cultureSAT-TB 27.27%, Xpert MTB/RIF 54.55%, MGIT 960 culture 45.45%Teklu B9 1976USACohort study44Löwenstein–Jensen culture, Middlebrook 7H10 culture, routine urinalysis, IVP, chest X-ray, tuberculin skin test, histopathologyFirst-morning urine, 24-hour urine, renal biopsy specimensStandard tuberculosis culture proceduresCulture, laboratory tests, imaging examinations, immunological tests, histopathologyCulture 91.00%Hemal AK10 2000IndiaCross-sectional study42PCR, Löwenstein–Jensen culture, bladder biopsy histopathology, acid-fast staining (urine smear), IVUFirst-morning urine, bladder tissue, pusCentrifugation at 3000 rpm for 30 minutes, sediment collection, Tris buffer suspension, compartmentalized PCR procedures, sediment inoculation on Löwenstein–Jensen mediumMolecular testing, culture, histopathology, microscopy, imaging examinationsPCR/NAAT 94.29%, AFB smear/staining 37.14%, Bladder biopsy 45.83%, CT/IVP imaging 91.42%Griffith DP11 1975USALaboratory study18Ziehl–Neelsen acid-fast staining, fluorescent acid-fast staining, Löwenstein–Jensen culture, Middlebrook 7H10 cultureInfected urineAddition of Mycobacterium tuberculosis at known concentrations, incubation at 37°C for 2 h or 10 h, centrifugation, sediment collection, staining, and culture inoculationMicroscopy, cultureLowenstein culture 85.00%, 7H-10 culture 85.00%, AFB smear/staining 25.00%, Fluorescence staining 25.00%Alberte Castiñeiras A12 2002SpainCohort study170Fluorescent acid-fast staining, Löwenstein–Jensen culture, pyruvate-containing culture medium, urine sediment microscopy, antimicrobial susceptibility testing (proportion method)First-morning urineDecontamination with 6% sulfuric acid, centrifugation and sediment collection, fluorescent staining, inoculation on Löwenstein–Jensen medium with incubation up to 8 weeks, inoculation on pyruvate-supplemented medium with incubation up to 8 weeks, centrifugation and sediment collection, microscopic examination, centrifugation and sediment collection, followed by antimicrobial susceptibility testing after cultureMicroscopy, culture, antimicrobial susceptibility testingFluorescence staining 45.00%Satoshi Takahashi13 2007JapanCase series12NAAT, culture (type not specified), antimicrobial susceptibility testing, histopathologyFirst-morning urine, renal tissueNAMolecular testing, culture, antimicrobial susceptibility testing, histopathologyPCR/NAAT 91.70%Jeong HJ6 2025South KoreaCohort study646Acid-fast staining, fluorescent acid-fast staining, culture (type not specified), MTB/NTM PCR, histopathology, imaging examinations, cystoscopyFirst-morning urine, bladder tissueNAMicroscopy, culture, molecular testing, histopathology, imaging examinations, endoscopyAFB smear/staining 71.40%, MTB & NTM PCR 42.90%Samuel BP14 2018IndiaCross-sectional study100Xpert MTB/RIF, fluorescent acid-fast staining, MGIT 960 culture, histopathologyFirst-morning urine, renal tissue, bladder tissueN-acetyl-L-cysteine–sodium hydroxide digestion, centrifugation and aliquotingMolecular testing, microscopy, culture, histopathologyXpert MTB/RIF 69.09%, MGIT 960 culture 56.36%, LED fluorescence smear 32.72%Wang Y15 2015ChinaDescriptive study192Acid-fast staining, culture (type not specified), histopathology, CT, KUB/IVPUrine, surgical tissueNAMicroscopy, culture, histopathology, imaging examinationsCT/IVP imaging 88.00%Aysegul Zumrutdal16 2013TürkiyeReviewNAPCR, liquid culture, Ziehl–Neelsen acid-fast staining, histopathology, imaging examinationsUrine, tissue biopsy, bloodNAMolecular testing, culture, microscopy, histopathology, imaging examinationsCulture 35.00%, AFB smear/staining 30.00%, PCR/NAAT 94.00%Mete Cek17 2005EuropeGuideline/ConsensusNALöwenstein–Jensen culture, acid-fast staining, PCR, histopathology, imaging examinationsFirst-morning urine, multiple-day urine samples, secretions, pus, semen, tissue biopsyCollection of 3–5 first-morning urine samples, timely inoculation and staining, cold storageCulture, microscopy, molecular testing, histopathology, imaging examinationsAFB smear/staining 51.50%, Lowenstein culture 35.00%, PCR/NAAT (Urine) 72.50%, PCR/NAAT (Tissue) 73.00%Maria Joao Matos18 2005PortugalReviewNAImaging examinationsImagingNAImaging examinationsNAWang LJ19 2003Taiwan, ChinaCase series53IVP, CTImagingNAImaging examinationsNAE. Gómez20 1998SpainCase series3Ziehl–Neelsen acid-fast staining, Löwenstein–Jensen cultureUrineContinuous collection over multiple days, repeated staining, repeated cultureMicroscopy, cultureNAMurray S. Feldstein21 1975USACase series42Löwenstein–Jensen culture, histopathology, IVP, retrograde pyelography, ultrasonographyUrine, surgical tissueNACulture, histopathology, imaging examinationsNAJohn K. Lattimer22 1969USACohort study33324-hour urine culture, first-morning urine culture, animal inoculation (guinea pig method)UrineBatch collection of 24-hour urine and first-morning urine samples, multiple submissions for testingCulture, animal experimentsCulture 54.70%Ajaz Nabi Koul23 2018IndiaCross-sectional diagnostic study46Ziehl–Neelsen acid-fast staining, Löwenstein–Jensen culture, Xpert MTB/RIFUrineCollection of first-morning urine over multiple days, submission of multiple specimensMicroscopy, culture, molecular testingCulture 28.00%, Xpert MTB/RIF 39.00%Amit Kumar Adhya24 2010IndiaCase series1Urine cytology, Ziehl–Neelsen acid-fast staining, culture (type not specified)UrineContinuous multi-day urine collection, cytological slide preparation, Ziehl–Neelsen stainingCytological examination, microscopy, cultureNAHuang C-T25 2010Taiwan, ChinaCase series58NTM isolation culture, 16S rRNA sequencing, acid-fast staining, histopathology, imaging examinationsUrine, prostate biopsy tissue, epididymal biopsy tissueCulture and molecular identification performed according to guidelinesCulture, molecular testing, microscopy, histopathology, imaging examinationsNA Characteristics of Included Studies on Laboratory Diagnostic Tests for Genitourinary Tuberculosis Evidence Distribution and Evidence Matrix Analysis An evidence matrix was constructed to systematically illustrate the distribution of laboratory diagnostic tests for genitourinary tuberculosis across different specimen types (Figure 2). In the evidence matrix, diagnostic methods are displayed on the horizontal axis and specimen types on the vertical axis. The numbers and color intensity within each cell represent the number of included studies corresponding to a given combination of diagnostic method and specimen type, with darker colors indicating a greater volume of available evidence. Evidence matrix showing the distribution of diagnostic methods across specimen types for genitourinary tuberculosis. The results indicate that first-morning urine and routine urine were the most frequently used specimen types, covering a wide range of diagnostic methods, including Löwenstein–Jensen culture, acid-fast staining, polymerase chain reaction, and Xpert MTB/RIF. Among these, combinations of first-morning urine with Löwenstein–Jensen culture, polymerase chain reaction, and Xpert MTB/RIF were supported by three to four studies, representing the most evidence-rich areas within the current literature. Other specimen types, such as bladder tissue, pus, 24-hour urine, and tissue biopsy, were reported in association with selected diagnostic methods (eg, histopathology and Middlebrook culture), but the number of included studies was relatively limited. Evidence supporting emerging molecular diagnostic technologies—including 16S rRNA sequencing, simultaneous amplification testing for tuberculosis, and metagenomic next-generation sequencing—remains scarce, with only single studies reported for a small number of specimen types. Conventional bacteriological methods (including Löwenstein–Jensen culture, acid-fast staining, and Ziehl–Neelsen staining) and molecular diagnostic methods (including polymerase chain reaction and Xpert MTB/RIF) were most frequently applied to urine and first-morning urine specimens. In contrast, relatively few studies evaluated tissue-based specimens or special specimen types, including renal biopsy, epididymal biopsy, prostate biopsy, semen, and blood specimens. Bubble Plot Analysis of Diagnostic Sensitivity and Turnaround Time To visually compare the diagnostic sensitivity and turnaround time of different laboratory testing methods across various specimen types, an evidence-based bubble plot was constructed (Figure 3). In this plot, diagnostic methods are displayed on the horizontal axis and specimen types on the vertical axis. Bubble size represents diagnostic sensitivity, while bubble color reflects turnaround time, with darker colors indicating longer processing times. Bubble plot showing diagnostic sensitivity and turnaround time across diagnostic methods and specimen types. The bubble plot showed that molecular diagnostic methods, including PCR/NAAT, Xpert MTB/RIF, and SAT-TB, were mainly evaluated using urine and first-morning urine specimens. Across included studies, the reported diagnostic sensitivity ranged from 42.9% to 94.3% for PCR/NAAT-based methods and from 39.0% to 89.0% for Xpert MTB/RIF. SAT-TB was evaluated in a limited number of studies, with reported sensitivity ranging from 27.3% to 72.7% in urine-based specimens. Detailed turnaround time data were inconsistently reported across included studies; however, molecular diagnostic assays were generally categorized as rapid diagnostic methods in the reviewed literature. Conventional bacteriological methods, including Löwenstein–Jensen culture, Mycobacteria Growth Indicator Tube (MGIT) 960 culture, and acid-fast bacilli staining, showed greater variability in reported diagnostic sensitivity across studies. Reported sensitivity ranged from 35.0% to 85.0% for Löwenstein–Jensen culture–based methods, from 45.5% to 56.4% for MGIT 960 culture, and from 25.0% to 71.4% for acid-fast bacilli staining. Detailed turnaround time information for culture-based methods was infrequently reported in the included studies. Histological examinations, including bladder biopsy and histopathological assessment, showed variable reported diagnostic sensitivity across included studies, with reported sensitivity generally ranging from 45.8% to 93.0%. Imaging-based investigations were evaluated less frequently, and detailed turnaround time information was rarely reported across studies. Overall, substantial variation in reported diagnostic sensitivity and turnaround time was observed across diagnostic methods and specimen types. Quality Assessment of Included Studies All included studies were systematically assessed for risk of bias using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool, covering four domains: patient selection, index test, reference standard, and flow and timing. An overall risk-of-bias judgment was then assigned based on assessments across these domains. Across the evaluated domains, a relatively high proportion of studies were rated as having high or unclear risk of bias in the domains of patient selection and flow and timing, indicating potential limitations related to sample inclusion criteria and the standardization of diagnostic procedures in some studies. Detailed results of the quality assessment are presented in Table 2 and Figure 4. Table 2Quality Assessment of Included Studies Using QUADAS-2 and OCEBMAssessment toolAuthorOverall Risk of BiasQUADAS-2 (n=17)Yu Chen7Low riskMallya A8High riskZhao Wei2Low riskTeklu B9High riskHemal AK10Low riskGriffith DP11High riskAlberte Castiñeiras A12High riskSatoshi Takahashi13High riskJeong HJ6Low riskSamuel BP14Low riskWang Y15High riskWang LJ19High riskE. Gómez20High riskMurray S. Feldstein21High riskJohn K. Lattimer22High riskAjaz Nabi Koul23High riskHuang C-T25Low riskOCEBM (n=4)Aysegul Zumrutdal16Level 5Mete Cek17Level 1Maria Joao Matos18Level 5Amit Kumar Adhya24Level 5 Quality Assessment of Included Studies Using QUADAS-2 and OCEBM Risk of bias and evidence level assessment of included studies. Analysis of Diagnostic Method–Specimen Type–Sensitivity Relationships To further characterize the multidimensional relationships among diagnostic methods, specimen types, and diagnostic sensitivity, an evidence-based Sankey diagram was constructed (Figure 5). The Sankey diagram uses directional flows to present associations between major diagnostic methods, specimen types, and predefined sensitivity categories (<50%, 50–80%, and >80%). Sankey diagram illustrating relationships among diagnostic methods, specimen types, and diagnostic sensitivity categories. The Sankey diagram showed that molecular diagnostic methods, including Xpert MTB/RIF, polymerase chain reaction/nucleic acid amplification tests (PCR/NAAT), and simultaneous amplification testing for tuberculosis (SAT-TB), were primarily linked to the high-sensitivity category (>80%) when applied to urine and first-morning urine specimens. In contrast, conventional culture-based methods, including Mycobacteria Growth Indicator Tube (MGIT) 960 culture, Löwenstein–Jensen culture, and Middlebrook 7H10 culture, as well as acid-fast bacilli staining, demonstrated greater flow distribution within the moderate- or low-sensitivity categories. Histological examinations and imaging-based diagnostic approaches showed relatively dispersed flow distributions across different sensitivity categories. In addition, fewer studies were available for special specimen types and emerging diagnostic methods, resulting in relatively sparse flow distributions within the Sankey diagram. Overall, the Sankey diagram integrated diagnostic methods, specimen types, and sensitivity categories into a unified flow structure and demonstrated distinct distribution patterns across different diagnostic pathways. Discussion Interpretation of the Main Findings This study systematically summarized and visualized the current evidence on laboratory diagnostic tests for genitourinary tuberculosis, focusing on the relationships among diagnostic methods, specimen types, diagnostic sensitivity, and turnaround time. Three main findings were identified from the evidence atlas. First, molecular diagnostic methods, particularly Xpert MTB/RIF and polymerase chain reaction/nucleic acid amplification tests (PCR/NAAT), were the most frequently studied diagnostic approaches in routine urine and first-morning urine specimens. Compared with conventional bacteriological methods, these molecular techniques generally showed higher diagnostic sensitivity and shorter turnaround times. These findings are consistent with the growing use of rapid molecular diagnostic technologies in tuberculosis diagnosis. Second, the evidence matrix, bubble plot, and Sankey diagram provided a structured overview of the relationships among diagnostic methods, specimen types, and diagnostic performance. Urine-based specimens combined with molecular diagnostic methods represented the most evidence-rich area in the current literature. In contrast, studies involving histological examinations, special specimen types, and emerging molecular diagnostic technologies were relatively limited. These results highlight several areas where further evidence is still needed. Third, the quality of the available evidence was unevenly distributed across diagnostic approaches. Most high-quality studies focused on commonly used molecular diagnostic methods and routine urine specimens, whereas evidence related to special populations, complex clinical cases, and newer diagnostic technologies remained limited. This imbalance may affect the overall completeness and applicability of current diagnostic strategies for genitourinary tuberculosis. Overall, this study provides a structured evidence atlas integrating specimen types, laboratory diagnostic methods, diagnostic sensitivity, and turnaround time for genitourinary tuberculosis. By combining evidence matrices, bubble plots, and Sankey diagrams, the study summarizes current evidence distribution patterns and highlights important research gaps in GUTB diagnostics. Strengths and Limitations of Different Diagnostic Tests The evidence atlas constructed in this study demonstrates that laboratory diagnostic approaches for genitourinary tuberculosis are diverse, with each testing modality presenting distinct strengths and limitations. Appropriate selection of diagnostic strategies therefore requires integration of clinical needs, specimen characteristics, and resource availability. Conventional Diagnostic Methods Smear microscopy (eg, acid-fast bacilli staining) has long been used as a primary screening tool in primary healthcare settings and resource-limited regions because of its low cost, operational simplicity, and rapid turnaround time. However, its diagnostic sensitivity is relatively low, particularly in genitourinary specimens with low bacterial loads, leading to a high risk of missed diagnoses. In addition, smear microscopy cannot reliably differentiate Mycobacterium tuberculosis from nontuberculous mycobacteria, limiting its utility for definitive diagnosis and differential diagnosis.4,23 Mycobacterial culture methods, such as Mycobacteria Growth Indicator Tube (MGIT) 960 culture and Löwenstein–Jensen culture, are still regarded as the diagnostic gold standard owing to their high specificity and ability to provide drug susceptibility information. Nevertheless, their sensitivity is strongly influenced by bacterial burden and specimen type, and culture results often require several weeks. This prolonged turnaround time substantially limits timely clinical decision-making, and culture positivity remains relatively low in complex cases, including immunocompromised patients.2,6,7 Molecular Diagnostic Methods Xpert MTB/RIF represents a widely used rapid molecular diagnostic assay with advantages including operational convenience, short turnaround time (approximately two hours), high specificity, and simultaneous detection of rifampicin resistance. It has been extensively applied to urine and first-morning urine specimens and has been recommended by the World Health Organization as an adjunctive diagnostic tool for urinary tract and other forms of tuberculosis.2,7,26 Multiple studies have reported a diagnostic sensitivity for genitourinary tuberculosis ranging from approximately 41.3% to 69.1%, with specificity approaching 100%. However, its relatively high cost and technical requirements limit large-scale implementation in resource-constrained settings. Moreover, the inability to distinguish viable from nonviable bacteria may result in false-positive results in certain clinical scenarios.2,8–13,27,28 Simultaneous amplification testing for tuberculosis (SAT-TB), based on 16S rRNA amplification, offers rapid detection, lower cost (approximately USD 30 per test), favorable performance in low-bacterial-load specimens, and a relatively low risk of contamination, making it suitable for large-scale screening and application in primary laboratories.2 However, its global adoption remains limited, and large multicenter studies are lacking. Some studies suggest that its diagnostic sensitivity may be slightly lower than that of Xpert. Other molecular approaches, including polymerase chain reaction and nucleic acid amplification tests (PCR/NAAT), have also demonstrated higher sensitivity and efficiency than conventional methods, but their lack of standardization, higher costs, and technical complexity, as well as susceptibility to specimen quality and laboratory conditions, remain important limitations. Histological and Imaging Examinations Histological examination is particularly valuable for complex or diagnostically challenging cases requiring pathological confirmation, and can compensate for missed diagnoses associated with bacteriological methods. However, its invasive nature and the difficulty of specimen acquisition limit routine clinical use, and patient acceptance may be suboptimal.13–15,27,28 Imaging examinations, such as ultrasonography, computed tomography, and intravenous urography, play an important role in assessing structural abnormalities of the genitourinary system and contribute to early screening and adjunctive diagnosis of suspected genitourinary tuberculosis. Nevertheless, their limited specificity and potential for missed early-stage disease necessitate combination with microbiological and molecular diagnostic tests.16–18 Integrated Diagnostic Strategies and Future Trends Current diagnostic recommendations generally advocate the combined use of molecular diagnostic methods (such as Xpert MTB/RIF and SAT-TB) with conventional culture, along with multi-specimen and multi-time-point testing to enhance diagnostic sensitivity. For complex or refractory cases, histological and imaging examinations serve as important complementary tools. Emerging molecular technologies, such as metagenomic next-generation sequencing (mNGS), have the potential to further refine diagnostic strategies; however, additional high-quality clinical studies are required to validate their effectiveness, cost-effectiveness, and accessibility.2,19–22,24–26,29,30 Overall, laboratory diagnosis of genitourinary tuberculosis requires a multimodal approach that integrates molecular diagnostics, conventional culture, and adjunctive examinations. Selection of diagnostic approaches should consider specimen type, clinical presentation, and resource availability. Evidence Gaps and Future Research Directions Although considerable evidence has been accumulated for urine-based specimens and commonly used molecular diagnostic methods in genitourinary tuberculosis, several important gaps remain in the current literature. Previous reports have also highlighted the diagnostic pitfalls, nonspecific clinical manifestations, and delayed recognition commonly encountered in genitourinary tuberculosis, particularly in paucibacillary cases and atypical clinical presentations.26 First, evidence related to special specimen types and complex clinical cases remains limited. Most published studies have focused on routine urine and first-morning urine specimens, whereas studies involving bladder biopsy, pus, prostatic fluid, blood, and other special specimens are relatively scarce. In addition, evidence regarding patients with complicated underlying diseases or atypical clinical presentations is still insufficient. The lack of large-scale studies limits the establishment of more individualized diagnostic strategies for these patient groups. Second, evidence for emerging molecular diagnostic technologies remains limited. Although methods such as metagenomic next-generation sequencing (mNGS), 16S rRNA sequencing, and CRISPR-based assays have shown potential in tuberculosis diagnosis, current studies are mostly single-center investigations with relatively small sample sizes. More prospective multicenter studies are needed to further evaluate their diagnostic performance, clinical applicability, and cost-effectiveness. Third, studies involving high-risk populations and special clinical scenarios are still lacking. Evidence related to immunocompromised patients, kidney transplant recipients, long-term dialysis patients, children, and older adults remains limited. In addition, relatively few studies have evaluated diagnostic strategies in mixed infections, multidrug-resistant tuberculosis, or diagnostically challenging cases. Future research should focus on multicenter prospective studies involving special specimen types, complex clinical cases, and high-risk populations. Additional validation studies are also needed for emerging molecular diagnostic technologies in different clinical settings. Strengthening evidence in these areas may help improve the completeness and applicability of laboratory diagnostic strategies for genitourinary tuberculosis. Limitations of the Study Several limitations of this study should be acknowledged. First, most included studies were retrospective and single-center in design, and sample sizes varied considerably across studies. In addition, some studies provided incomplete information regarding specimen processing procedures, diagnostic thresholds, or turnaround time, which may have affected the consistency and comparability of the extracted data. Second, substantial heterogeneity existed among the included studies with respect to specimen types, laboratory methods, reference standards, and reporting of diagnostic sensitivity. For example, urine specimens included routine urine, first-morning urine, and 24-hour urine collected using different processing procedures, while molecular diagnostic methods also differed across studies. This heterogeneity limited direct comparisons between diagnostic approaches. Third, evidence for several special specimen types and emerging molecular diagnostic technologies remained limited. As shown in the evidence matrix and Sankey diagram analyses, studies involving tissue biopsy, blood specimens, metagenomic next-generation sequencing (mNGS), and other novel diagnostic approaches were relatively scarce, and most were based on small sample sizes or specific populations. As a result, the corresponding evidence base remains limited. In addition, this study mainly relied on published literature indexed in major databases, and publication bias or incomplete literature retrieval cannot be completely excluded. Although no language restrictions were applied during the literature search process, most included studies were published in English. Despite these limitations, this study provides a structured overview of the current evidence landscape of laboratory diagnostics for genitourinary tuberculosis. The evidence atlas may help identify current research hotspots and evidence gaps and may provide a reference for future studies in this field. Therefore, the findings of this evidence atlas should be interpreted in the context of the heterogeneity and limitations of the currently available literature. Conclusions Using an evidence atlas approach, this study systematically mapped the evidence distribution and structural characteristics of laboratory diagnostic tests for genitourinary tuberculosis. The findings indicate that urine and first-morning urine specimens combined with molecular diagnostic methods—such as Xpert MTB/RIF, polymerase chain reaction/nucleic acid amplification tests (PCR/NAAT), and simultaneous amplification testing for tuberculosis (SAT-TB)—represent the most evidence-rich diagnostic pathway in the current literature and generally demonstrate relatively higher diagnostic sensitivity and shorter turnaround times. In contrast, conventional culture-based and histological methods, although still clinically valuable, remain limited by variability in diagnostic sensitivity and longer processing times. The evidence atlas also identified several important gaps in the current literature, including limited evidence related to special specimen types, emerging molecular diagnostic technologies, and high-risk populations. Overall, this study provides a structured overview of the current evidence landscape of laboratory diagnostics for genitourinary tuberculosis and may serve as a reference for future studies and further development of diagnostic strategies in this field. Highlights This study constructed an evidence atlas of laboratory diagnostic tests for genitourinary tuberculosis. Urine and first-morning urine were the most frequently investigated specimen types in the current literature. Molecular diagnostic methods, particularly Xpert MTB/RIF and PCR/NAAT, represented the most evidence-rich diagnostic approaches. Evidence regarding special specimen types and emerging molecular diagnostic technologies remains limited. Multidimensional visualization methods helped identify current research hotspots and evidence gaps in GUTB diagnostics. Abbreviations TB, Tuberculosis; EPTB, Extrapulmonary tuberculosis; Mtb, Mycobacterium tuberculosis; GUTB, Genitourinary tuberculosis; PCR, Polymerase chain reaction; NAAT, Nucleic acid amplification test; SAT-TB, Simultaneous amplification testing for tuberculosis; MGIT, Mycobacteria Growth Indicator Tube; WHO, World Health Organization. Disclosure The authors report no conflicts of interest in this work. References